Research progress in pharmacogenic cardiotoxicity

doi:10.19803/j.1672-8629.20230293

Abstract

Abstract: Pharmacogenic cardiotoxicity is one of the severe adverse reactions triggered by drugs, the severity of which ranges from mild electrocardiographic changes to fatal arrhythmias. Pharmacogenic cardiotoxicity is characterized by multiple sources, high incidence, insidiousness, susceptibility to special populations, diversity of clinical manifestations, and complexity of mechanisms. In recent years, research on pharmacogenic cardiotoxicity has received much attention. This paper reviews the research progress in pharmacogenic cardiotoxicity in terms of its clinical manifestations, mechanisms of occurrence and preventive measures to provide reference for clinical prevention of pharmacogenic cardiotoxicity.

Key words: pharmacogenic, cardiotoxicity, arrhythmias, clinical manifestations, clinical characteristic, mechanisms, preventive measures

CLC Number:

R994.11

ZHANG Bing, SA Rina, ZHANG Xiaomeng, ZHANG Dan, LIN Zhijian, WANG Yu. Research progress in pharmacogenic cardiotoxicity[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 841-847.

References

[1] LOPEZ-GONZALEZ E, HERDEIRO M T, FIGUEIRAS A.Determinants of under-reporting of adverse drug reactions: a systematic review[J]. Drug Saf, 2009, 32(1): 19-31.
[2] Hubei Food and Drug Administration. Prevention and treatment of pharmacogenic cardiovascular diseases(药源性心血管系统疾病的防治)[M]. Wuhan: Hubei People's Press, 2012.
[3] Chinese Society of Clinical Oncology, Hematology Branch of Chinese Medical Association. Guidelines for the prevention and treatment of cardiotoxicity of anthracyclines (2020 version) (蒽环类药物心脏毒性防治指南2020版)[M]. Beijing: People's Medical Publishing House, 2020.
[4] PAN XQ, YAN BH, ZHOU J, et al.Research Progress of Chinese materia medica-induced cardiotoxicity[J]. Progress in Pharmaceutical Sciences(药学进展), 2020, 44(10): 730-742.
[5] SHEN JY, LV LC,WEI TM.Current status and latest research progress in onco-cardiology[J]. Journal of Electrocardiology and Circulation(心脏病学与循环杂志), 2022, 41(1): 88-92, 98.
[6] LENNEMAN CG, SAWYER DB.Cardio-Oncology: An update on cardiotoxicity of cancer-related treatment[J]. Circ Res, 2016, 118(6): 1008-1020.
[7] SLAMON DJ, LEYLAND-JONES B, SHAK S, et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-792.
[8] SINGH JC, JHAVERI K, ESTEVA F J.HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development[J]. Br J Cancer, 2014, 111(10): 1888-1898.
[9] WALIANY S, ZHU H, WAKELEE H, et al.Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC[J]. J Thorac Oncol, 2021, 16(12): 2029-2039.
[10] KUNIMASA K.Is osimertinib-induced cardiotoxicity really harmless?[J]. J Clin Oncol, 2021, 39(18): 2050-2051.
[11] DORKS M, JOBSKI K, HERGET-ROSENTHAL S, et al.Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-A pharmacovigilance analysis[J]. Pharmacol Res Perspect, 2021, 9(1): e00707.
[12] YUAN M, LIU T.Research advance in cardiotoxicity associated with tyrosine kinases inhibitor therapy[J]. Progress in Pharmaceutical Sciences(药学进展), 2018, 42(7): 512-516.
[13] WAN Q, LI Q, LAI X, et al.Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database[J]. Front Pharmacol, 2022, 13: 995522.
[14] SALEM JE, MANOUCHEHRI A, MOEY M, et al.Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study[J]. Lancet Oncol, 2018, 19(12): 1579-1589.
[15] MASCOLO A, SCAVONE C, FERRAJOLO C, et al.Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance[J]. Drug Saf, 2021, 44(9): 957-971.
[16] HAUGNES HS, WETHAL T, AASS N, et al.Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study[J]. J Clin Oncol, 2010, 28(30): 4649-4657.
[17] HASHIMOTO Y, YOSHIDA Y, YAMADA T, et al.Current status of therapeutic drug monitoring of 5-fluorouracil prodrugs[J]. Anticancer Res, 2020, 40(8): 4655-4661.
[18] JOSHI AM, PROUSI GS, BIANCO C, et al.Microtubule inhibitors and cardiotoxicity[J]. Curr Oncol Rep, 2021, 23(3): 30.
[19] KATAYAMA M, IMAI Y, HASHIMOTO H, et al.Fulminant fatal cardiotoxicity following cyclophosphamide therapy[J]. J Cardiol, 2009, 54(2): 330-334.
[20] VON BERNUTH G, ADAM D, HOFSTETTER R, et al.Cyclophosphamide cardiotoxicity[J]. Eur J Pediatr, 1980, 134(1): 87-90.
[21] MA F, XU BH, SHAO ZM, et al.Comprehensive management guideline for breast cancer follow-up and concomitant diseases[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2019, 41(1): 29-41.
[22] MATTHEWS A, STANWAY S, FARMER RE, et al.Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review[J]. BMJ, 2018, 363(k3845):1-11.
[23] TOOKE CL, HINCHLIFFE P, BRAGGINTON EC, et al.beta-Lactamases and beta-Lactamase Inhibitors in the 21st Century[J]. J Mol Biol, 2019, 431(18): 3472-3500.
[24] PATEL H, CALIP GS, DIDOMENICO RJ, et al.Comparison of cardiac events associated with azithromycin vs amoxicillin[J]. JAMA Netw Open, 2020, 3(9): e2016864.
[25] YANG YF, LIN L, LI M.Cardiotoxicity of common antimicrobial drugs[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2007, 27(10): 1437-1439,1490.
[26] ZHANG J, WANG JH, LIU L, et al.Literature analysis of 65 cases of ADR in cardiovascular system induced by β-Lactam antibiotics[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2013, 10(4): 238-241.
[27] ETCHEGOYEN CV, KELLER GA, MRAD S, et al.Drug-induced QT interval prolongation in the intensive care unit[J]. Curr Clin Pharmacol, 2017, 12(4): 210-222.
[28] FROMMEYER G, FISCHER C, ELLERMANN C, et al.Additive Proarrhythmic effect of combined treatment with QT-prolonging agents[J]. Cardiovasc Toxicol, 2018, 18(1): 84-90.
[29] PODGURSKAYA AD, TSVELAYA VA, SLOTVITSKY MM, et al.The Use of iPSC-Derived cardiomyocytes and optical mapping for erythromycin arrhythmogenicity testing[J]. Cardiovasc Toxicol, 2019, 19(6): 518-528.
[30] LI H, LIN ZX.Retrospective analysis of 90 cases of adverse reactions to erythromycin[J]. Journal of Guangdong Pharmaceutical University(广东药科大学学报), 2000, 16(3): 231-232.
[31] OWENS RC, JR, AMBROSE PG.Torsades de pointes associated with fluoroquinolones[J]. Pharmacotherapy, 2002, 22(5): 663-672.
[32] STAHLMANN R, LODE H.Toxicity of quinolones[J]. Drugs, 1999, 58(Suppl 2): 37-42.
[33] RUBINSTEIN E, CAMM J.Cardiotoxicity of fluoroquinolones[J]. J Antimicrob Chemother, 2002, 49(4): 593-596.
[34] FROTHINGHAM R.Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin[J]. Pharmacotherapy, 2001, 21(12): 1468-1472.
[35] YANG Q, WANG XJ, YOU QD.Cardiotoxic side effects of drugs, their mechanisms and prevention strategies (Part 1)[J]. China Pharmacist(中国药师), 2008, 101(6): 641-643, 645.
[36] ROTELLA JA, GREENE SL, KOUTSOGIANNIS Z, et al.Treatment for beta-blocker poisoning: a systematic review[J]. Clin Toxicol (Phila), 2020, 58(10): 943-983.
[37] SHEPHERD G.Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers[J]. Am J Health Syst Pharm, 2006, 63(19): 1828-1835.
[38] ALSHAYA O A, ALHAMED A, ALTHEWAIBI S, et al.Calcium channel blocker toxicity: a practical approach[J]. J Multidiscip Healthc, 2022, 8(15): 1851-1862.
[39] ROBERTSON JI.Diuretics, potassium depletion and the risk of arrhythmias[J]. Eur Heart J, 1984, 5(Suppl A): 25-28.
[40] CHEN ZX.Advances in the clinical use of amiodarone against cardiac arrhythmias[J]. Proceeding of Clinical Medicine(临床医药实践), 2009, 18(13): 323-325.
[41] ROBERT M, DE BELS D, CHAUMONT M, et al.Angiotensin converting enzyme inhibitor intoxication: Naloxone to the rescue? Naloxone for ACE inhibitor intoxication[J]. Am J Emerg Med, 2019, 37(6): 1217e1211-1217e1212.
[42] TSUJIMOTO T, KAJIO H.Use of nitrates and risk of cardiovascular events in patients with heart failure with preserved ejection Fraction[J]. Mayo Clin Proc, 2019, 94(7): 1210-1220.
[43] WU CL.An introduction to Digitalis glycosides poisoning[J]. World Latest Medicine Information(世界最新医学信息文摘), 2015, 15(55): 133-134.
[44] MOORE N.Coronary risks associated with diclofenac and other NSAIDs: an update[J]. Drug Saf, 2020, 43(4): 301-318.
[45] ANTMAN EM.Evaluating the cardiovascular safety of nonsteroidal anti-inflammatory drugs[J]. Circulation, 2017, 135(21): 2062-2072.
[46] NADESALINGAM K, KIRBY D.Cardiovascular safety of non-steroidal anti-inflammatory drugs[J]. Br J Gen Pract, 2013, 63(617): 632.
[47] YANG X, XIA DS, TIAN CH, et al.Literature analysis of 508 cases reports of adverse reactions induced by Aconiti Lateralis Radix Praeparata[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(10): 615-621.
[48] WANG D, JIA DX, LI ZZ, et al.Safety evaluation and risk control measures for Aconiti Kusnezoffii Radix[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2018, 43(15): 3093-3100.
[49] YANG DM, LIU J.Study progress on clinical application and adverse reactions of tripterygium glycosides[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2018, 38(20): 2185-2190.
[50] LI YL, TAN XY.A literature survey and analysis of 294 cases of adverse reactions to Tripterygium wilfordii[J]. Shanxi Medical Journal(山西医药杂志), 2011, 40(1): 88-90.
[51] FAN YH, HANG PZ, DU ZM.Alteration of protein kinase C-E in arsenic trioxide-induced cardiomyocyte apoptosis[J]. Chinese Pharmacological Bulletin(中国药理学通报), 2013, 29(6): 782-786.
[52] LI M, LI H, WANG XJ, et al.Progress of experimental research on cardiotoxicity of Chansu[J]. Chinese Journal of Pharmacology and Toxicology(中国药理学与毒理学杂志), 2016, 30(5): 605-610.
[53] WU XJ, MA FS, ZHENG GL, et al.Toxicity research progress on indole alkaloids of strychni semen[J]. Pharmacology and Clinics of Chinese Materia Medica(中药药理与临床), 2016, 32(6): 231-235.
[54] DENG YH, CHEN L, PENG M, et al.In vitro and in vivo evaluation of the cardiotoxicity of evodiamine[J]. China Pharmacist(中国药师), 2021, 24(4): 653-657.
[55] CHEN LY, YU R, MA JY, et al.Clinical adverse reactions of realgar[J]. Information on Traditional Chinese Medicine(中医药信息), 2018, 35(6): 17-20.
[56] HAN EJ, PARK JS.Lethal arrhythmia induced by licorice[J]. J Korean Med Sci, 2023, 38(12): e107.
[57] YI LX.Studies on the pharmacokinetics metabonomics of cardiac toxic componentin Cortex Periplocae[D]. Shenyang:Shenyang Pharmaceutical University, 2010.
[58] DONG LC, XIAO HM, JIANG L, et al.The integrated pharmacokinetics of major rhodojaponins correlates with the cardiotoxicity after oral administration of Rhododendri Mollis Flos extract in rats[J]. Journal of Ethnopharmacology, 2014, 157: 69-78.
[59] SHAO HZ, MA QX, HU XW, et al.Target organ for acute toxicity of cantharidin[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2018, 24(16): 55-60.
[60] SONG Y, WANG Z, WU KD, et al.Study on the pharmacological action of scorpion poison[J]. Journal of Liaoning University of Traditional Chinese Medicine(辽宁中医药大学学报), 2020, 22(12): 216-220.
[61] BAHLOUL M, CHABCHOUB I, CHAARI A, et al.Scorpion envenomation among children: clinical manifestations and outcome (analysis of 685 cases)[J]. Am J Trop Med Hyg, 2010, 83(5): 1084-1092.
[62] QIANG GF, FANG LH, DU GH.The historical cognition and evaluation of centipedetoxicity[J]. Pharmacology and Clinics of Chinese Materia Medica(中药药理与临床), 2019, 35(2): 151-154.
[63] YANG P, WANG C, SUN Y, et al.Study on safety of scolopendra used for anti-tumor therapy[J]. Modern Chinese Medicine(中国现代中药), 2019, 21(3): 414-418.
[64] DING T, LUO JY, HAN X, et al.Advances of toxicity evaluation of cinnabar and compatibility necessity analysis[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2016, 41(24): 4533-4540.
[65] ZHANG XF.Research progress of toxicity and detoxification mechanism of Euphorbia kansui[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2014, 34(18): 1611-1615.
[66] HAN JT.The pharmacological effects and clinical applications of the multibanded krait[J]. Journal of Modern Medicine & Health(现代医药卫生), 2008, 24(14): 2132-2133.
[67] WANG BX, CUI JC, LIU AJ.Studies on pharmacological action of saponin of the root of anemone raddeana[J]. Journal of Traditional Chinese Medicine, 1985, 5(1): 61-64.
[68] ZHOU HL, SUN YX, LI Y, et al.Progress in studies on chemical constituents and pharmacological effect of Anemone Raddeana Regel[J]. Lishizhen Medicine and Materia Medica Research(时珍国医国药), 2007, 140(5): 1239-1241.
[69] ZHANG SN, LI HM, LI XZ.Analysis on mechanism and material basis of cardiotoxicity induced by shandougen(Sophorae Tonkinensis Radix Et Rhizome) by combination of mixed omics and bioinformatics[J]. Chinese Archives of Traditional Chinese Medicine(中华中医药学刊), 2022, 40(10): 111-114, 270.
[70] LIU H, YANG JF, ZHAN RT.Overview and prospect on research of Caulis Erycibes[J]. Guangdong Agricultural Sciences(广东农业科学), 2012, 39(1): 36-39.
[71] WANG RQ, ZHANG L, YANG XY, et al.Toxic traditional chinese medicine of animal origin:Historica perspective and modern studies[J]. Herald of Medicine(医药导报), 2019, 38(11): 1425-1430.
[72] SUN R, WANG C.Research development on toxicity of Rhizoma Menispermi[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2009, 6(9): 546-549.
[73] CHEN ZY, ZHANG Y.Research progress in the cardiovascular toxicity of 15 toxic Chinesemateria medica[J]. Chinese Journal of New Drugs(中国新药杂志), 2021, 30(14): 1282-1288.
[74] ZHAO FH, HOU XT, HAO EW, et al.Chemical constituents, toxicology and pharmacological effect of Momordicae Semen[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2020, 26(3): 222-235.
[75] WANG JH, LI L, DU GH.The historical cognition and evaluation of Hyoscyami Semen toxicity[J]. Pharmacology and Clinics of Chinese Materia Medica(中药药理与临床), 2018, 34(5): 163-165.
[76] TIAN YH, XIA L, YANG C, et al.Mechanism and clinical prevention of sudden cardiac death caused byantipsychotics[J]. Anhui Journal of Preventive Medicine(安徽预防医学杂志), 2022, 28(5): 352-356.
[77] YANG ZK, LIANG P.Exploring the cardiotoxicity and mechanisms of antineoplastic drugs[J]. Clinical Journal of Medical Officers(临床军医杂志), 2022, 50(3): 321-324.
[78] CAO P, ZHANG ZQ.Application of metabonomics in the study of cardiotoxicity of antineoplastic drugs[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2023, 39(5): 752-756.
[79] HOU H, LIN C, ZHANG M, et al.Advances in study on novel anti-tumor drugs-induced cardiotoxicity and molecular mechanisms[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2022, 57(1): 8-14.